Literature DB >> 18519688

Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.

Wen Yang1, He-Xin Yan, Lei Chen, Qiong Liu, Ya-Qin He, Le-Xing Yu, Shu-Hui Zhang, Dan-Dan Huang, Liang Tang, Xiao-Ni Kong, Chao Chen, Shu-Qin Liu, Meng-Chao Wu, Hong-Yang Wang.   

Abstract

Adult hepatic progenitor (oval) cells are facultative stem cells in liver, which participate in a range of human liver diseases, including hepatocellular carcinoma (HCC). However, the molecular pathways regulating the expansion and differentiation of these cells are poorly understood. We show that active Wnt/beta-catenin signaling occurs preferentially within the oval cell population, and forced expression of constitutively active beta-catenin mutant promotes expansion of the oval cell population in the regenerated liver. More importantly, we identify a subpopulation of less differentiated progenitor-like cells in HCC cell lines and primary HCC tissues, which are defined by expression of the hepatic progenitor marker OV6 and endowed with endogenously active Wnt/beta-catenin signaling. These OV6(+) HCC cells possess a greater ability to form tumor in vivo and show a substantial resistance to standard chemotherapy compared with OV6(-) tumor cells. The fraction of tumor cells expressing OV6 is enriched after Wnt pathway activation, whereas inhibition of beta-catenin signaling leads to a decrease in the proportion of OV6(+) cells. In addition, the chemoresistance of OV6(+) HCC progenitor-like cells can be reversed by lentivirus-delivered stable expression of microRNA targeting beta-catenin. These results highlight the importance of the Wnt/beta-catenin pathway in activation and expansion of oval cells in normal rodent models and human HCCs. OV6(+) tumor cells may represent the cellular population that confers HCC chemoresistance, and therapies targeted to the Wnt/beta-catenin signaling may provide a specific method to disrupt this resistance mechanism to improve overall tumor control with chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519688     DOI: 10.1158/0008-5472.CAN-07-6691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  162 in total

1.  Growth factor- and cytokine-driven pathways governing liver stemness and differentiation.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 2.  Biology of the adult hepatic progenitor cell: "ghosts in the machine".

Authors:  Houda Darwiche; Bryon E Petersen
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 3.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 4.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

Review 5.  Stem cells in hepatocarcinogenesis: evidence from genomic data.

Authors:  Jens U Marquardt; Snorri S Thorgeirsson
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.

Authors:  Mei-Fang Quan; Li-Hong Xiao; Zhi-Hong Liu; Hui Guo; Kai-Qun Ren; Fei Liu; Jian-Guo Cao; Xi-Yun Deng
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

7.  Accomplishments in 2008 in the management of hepatobiliary cancers.

Authors:  Andrew X Zhu; Anthony El-Khoueiry; Josep M Llovet
Journal:  Gastrointest Cancer Res       Date:  2009-09

8.  Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.

Authors:  Alphonse E Sirica; Michael H Nathanson; Gregory J Gores; Nicholas F Larusso
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

9.  The CD133+CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma.

Authors:  Yun-Wen Zheng; Tomonori Tsuchida; Taiki Shimao; Bin Li; Takanori Takebe; Ran-Ran Zhang; Yu Sakurai; Yasuharu Ueno; Keisuke Sekine; Naoto Ishibashi; Makiko Imajima; Takuji Tanaka; Hideki Taniguchi
Journal:  Stem Cells Dev       Date:  2014-06-26       Impact factor: 3.272

Review 10.  Clinical implications of cancer stem cell biology in hepatocellular carcinoma.

Authors:  Junfang Ji; Xin Wei Wang
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.